Opiant Pharmaceuticals Investor Relations Material

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company's lead product candidate is naloxone nasal spray that is in Phase III clinical trial for the treatment of opioid overdose. It also engages in developing temporary user-based treatment targeting at treating binge eating disorder (BED); as well as nasal treatments for other addictive/compulsive behaviors and disorders.